Ligand price target lowered to $180 from $195 at Roth Capital
Roth Capital analyst Scott Henry lowered his price target for Ligand to $180 from $195 following its divestiture of the Promacta royalty stream. The analyst reiterates a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.